Mirum Pharmaceuticals Return On Equity Over Time
| MIRM Stock | USD 45.25 1.19 2.70% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Mirum Pharmaceuticals Performance and Mirum Pharmaceuticals Correlation. Mirum |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirum Pharmaceuticals. If investors know Mirum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirum Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.83) | Revenue Per Share | Quarterly Revenue Growth 0.429 | Return On Assets | Return On Equity |
The market value of Mirum Pharmaceuticals is measured differently than its book value, which is the value of Mirum that is recorded on the company's balance sheet. Investors also form their own opinion of Mirum Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Mirum Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirum Pharmaceuticals' market value can be influenced by many factors that don't directly affect Mirum Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mirum Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mirum Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirum Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Return On Equity Analysis
Compare Mirum Pharmaceuticals and related stocks such as Immunocore Holdings, Larimar Therapeutics, and Kalvista Pharmaceuticals Return On Equity Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMCR | (1.266) | (1.266) | (1.266) | (1.266) | (1.266) | (1.266) | (1.266) | (1.266) | (1.266) | (7.0362) | (1.3387) | (0.7667) | (0.1479) | (0.1499) | (0.1416) | (0.15) |
| LRMR | (1.7229) | (1.7229) | (1.7229) | (0.3982) | (0.3501) | (0.4393) | (0.4755) | (0.6652) | (0.658) | 33.3314 | (0.4719) | (0.7811) | (0.3082) | (0.4521) | (0.41) | (0.39) |
| KALV | (0.532) | (0.532) | 0.0726 | 0.1684 | 0.1636 | (0.532) | (0.5938) | (0.5799) | (0.2152) | (0.3476) | (0.173) | (0.3701) | (0.4649) | (0.613) | 0.1636 | 0.17 |
| LYRA | 0.0563 | 0.0563 | 0.0563 | 0.0563 | 0.0563 | 0.0563 | 0.0563 | 0.0563 | 0.0563 | (2.1961) | (0.2959) | (1.2359) | (0.6845) | (0.701) | (0.81) | (0.85) |
| TERN | (0.2452) | (0.2452) | (0.2452) | (0.2452) | (0.2452) | (0.2452) | (0.2452) | (0.2452) | (0.2452) | (16.3582) | (0.5915) | (0.3129) | (0.2179) | (0.3533) | (0.32) | (0.33) |
| ABOS | 0.6884 | 0.6884 | 0.6884 | 0.6884 | 0.6884 | 0.6884 | 0.6884 | 0.6884 | 0.6884 | 0.6884 | 0.394 | (0.8068) | (0.2144) | (0.1962) | (0.23) | (0.21) |
| INZY | 0.5019 | 0.5019 | 0.5019 | 0.5019 | 0.5019 | 0.5019 | 0.5019 | 0.5019 | 0.5019 | 0.5605 | (0.3532) | (0.5163) | (0.5519) | (0.5066) | (1.7643) | (1.68) |
| XFOR | 0.3851 | 0.3851 | 0.3851 | 0.3851 | 0.3851 | 0.3851 | 0.4062 | (0.5771) | (1.9917) | (0.438) | (0.8535) | (1.377) | (1.2676) | (1.9798) | (2.28) | (2.16) |
| DAWN | 1.3783 | 1.3783 | 1.3783 | 1.3783 | 1.3783 | 1.3783 | 1.3783 | 1.3783 | 1.3783 | 1.3783 | 0.7473 | 0.5525 | 0.4901 | (0.5452) | (0.1899) | (0.18) |
| MLTX | (8.0E-4) | (8.0E-4) | (8.0E-4) | (8.0E-4) | (8.0E-4) | (8.0E-4) | (8.0E-4) | (8.0E-4) | (8.0E-4) | (8.0E-4) | (8.0E-4) | 4.6066 | (1.3192) | (0.0726) | (0.2701) | (0.26) |
| APLS | (0.876) | (0.876) | (0.876) | (0.876) | (0.8158) | (1.3299) | (1.14) | (0.3425) | (0.7921) | (9.0511) | (1.686) | (3.7569) | (3.8392) | (2.7176) | (0.8658) | (0.91) |
| BPMC | 13.9786 | 13.9786 | 13.9786 | 13.9786 | (1.1371) | (0.3665) | (0.3402) | (0.2374) | (0.5648) | (0.7079) | 0.2135 | (0.6635) | (1.0832) | (3.8817) | (0.2246) | (0.21) |
| ARQT | 0.997 | 0.997 | 0.997 | 0.997 | 0.997 | 0.997 | 0.997 | 0.997 | 0.8027 | 0.6458 | (0.5014) | (0.6917) | (1.533) | (2.9565) | (0.8889) | (0.93) |
Mirum Pharmaceuticals and related stocks such as Immunocore Holdings, Larimar Therapeutics, and Kalvista Pharmaceuticals Return On Equity description
Return on Equity is the amount of Mirum Pharmaceuticals net income returned as a percentage of Mirum Pharmaceuticals equity. Return on equity measures Mirum Pharmaceuticals profitability by revealing how much profit Mirum Pharmaceuticals generates with the money shareholders have invested. A measure of the profitability of a business in relation to the equity, calculated by dividing net income by shareholder's equity.My Equities
My Current Equities and Potential Positions
| Mirum Pharmaceuticals | MIRM |
| Classification | Pharmaceutical Products |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 43.04
Check out Mirum Pharmaceuticals Performance and Mirum Pharmaceuticals Correlation. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Mirum Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.